Novo VP on stem cell agreement: "A US footprint is essential"
Danish drug group Novo Nordisk ensured itself access to US-based facilities for the production of stem cell-based therapies. The company can now produce for clinical trials with a potential cure against type 1 diabetes and initiate projects on several other diseases, alone or together with partners.
Last week, Novo Nordisk signed a deal with US-based Asterias Biotherapeutics, which granted the Danish drug group access to production facilities in the US and brought the company one step closer to the dream of conducting clinical trials with a stem cell-based diabetes therapy in future.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
